# Icosavax (stock symbol: ICVX) Logo in transparent PNG and SVG formats

## Icosavax Logo large

### Icosavax Logo large Download PNG (43.21 KB)

![Icosavax Logo large Download PNG (43.21 KB)](/img/orig/ICVX_BIG-c24320a2.png)

### Icosavax Logo large Download SVG (16.12 KB)

![Icosavax Logo large Download SVG (16.12 KB)](/img/orig/ICVX_BIG-4d37e2d6.svg)

## Icosavax Logo icon format

### Icosavax Logo icon format Download PNG (142.47 KB)

![Icosavax Logo icon format Download PNG (142.47 KB)](/img/orig/ICVX-342f3692.png)

### Icosavax Logo icon format Download SVG (15.85 KB)

![Icosavax Logo icon format Download SVG (15.85 KB)](/img/orig/ICVX-b932ce96.svg)

## Icosavax Logo large for dark backgrounds

### Icosavax Logo large for dark backgrounds Download PNG (27.45 KB)

![Icosavax Logo large for dark backgrounds Download PNG (27.45 KB)](/img/orig/ICVX_BIG.D-aad06304.png)

### Icosavax Logo large for dark backgrounds Download SVG (16.13 KB)

![Icosavax Logo large for dark backgrounds Download SVG (16.13 KB)](/img/orig/ICVX_BIG.D-87ab8f7e.svg)

## Icosavax Logo icon format for dark backgrounds

### Icosavax Logo icon format for dark backgrounds Download PNG (85.67 KB)

![Icosavax Logo icon format for dark backgrounds Download PNG (85.67 KB)](/img/orig/ICVX.D-cda41602.png)

### Icosavax Logo icon format for dark backgrounds Download SVG (15.74 KB)

![Icosavax Logo icon format for dark backgrounds Download SVG (15.74 KB)](/img/orig/ICVX.D-6fcf5030.svg)

## About Icosavax

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.

1. Website domain: icosavax.com
2. Employees: 34
3. Marketcap: $0.22 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
